Skip to main content
Top
Published in: BMC Neurology 1/2011

Open Access 01-12-2011 | Research article

Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosis

Authors: Jennifer M Kress-Bennett, Garth D Ehrlich, Ashley Bruno, J Christopher Post, Fen Z Hu, Thomas F Scott

Published in: BMC Neurology | Issue 1/2011

Login to get access

Abstract

Background

There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was to characterize changes in CD4+ T-lymphocyte expression in an unbiased manner following initiation of intramuscular (IM) IFN-β-1a treatment, and then to verify those findings using marker-specific assays.

Methods

Peripheral blood specimens were collected from twenty MS patients before and after treatment with intramuscular (IM) IFN-β-1a and were used for isolation of mononuclear cells (PBMCs). mRNA expression patterns of negatively-selected CD4+ T-cells from the PBMCs were analyzed using microarray gene expression technology. IL-12 and IL-23 receptor levels on PBMC-derived CD4+ T-cells were analyzed by flow cytometry. The phosphorylation status of Stat4 was measured by performing densitometry on western blots.

Results

Microarray analyses demonstrated that mRNA expression of the IL-12Rβ2 gene was uniformly up-regulated in response to IFN-β-1a treatment and was associated with an increased number of IL-12Rβ2+ CD4+ T-cells by flow cytometry in 4 of 6 patients. This finding was substantiated by demonstrating that Stat4 phosphorylation, a transcription factor for IL-12, was increased after treatment. Conversely, the number of IL-23R+ CD4+ T-cells was decreased following treatment.

Conclusions

The IL-12 receptor shares a common subunit, the IL-12Rβ2, with the IL-23 receptor. Both of these receptors have a probable role in regulating IL-17 and TH-17 cells, important mediators of inflammation in multiple sclerosis (MS). Thus, the changes in the numbers of CD4+ T-cells expressing these receptors in response to IFN-β-1a treatment may point to an important mechanism of action for this drug, but further large scale studies are needed to confirm these preliminary observations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arnason BG: Immunologic therapy of multiple sclerosis. Annu Rev Med. 1999, 50: 291-302. 10.1146/annurev.med.50.1.291.CrossRefPubMed Arnason BG: Immunologic therapy of multiple sclerosis. Annu Rev Med. 1999, 50: 291-302. 10.1146/annurev.med.50.1.291.CrossRefPubMed
2.
go back to reference Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol. 2005, 23: 683-747. 10.1146/annurev.immunol.23.021704.115707.CrossRefPubMed Sospedra M, Martin R: Immunology of multiple sclerosis. Annu Rev Immunol. 2005, 23: 683-747. 10.1146/annurev.immunol.23.021704.115707.CrossRefPubMed
3.
go back to reference Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F: T-Helper 17 Cells Expand in Multiple Sclerosis and Are Inhibited by Interferon-β. Ann Neurol. 2009, 65: 499-509. 10.1002/ana.21652.CrossRefPubMed Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F: T-Helper 17 Cells Expand in Multiple Sclerosis and Are Inhibited by Interferon-β. Ann Neurol. 2009, 65: 499-509. 10.1002/ana.21652.CrossRefPubMed
4.
go back to reference Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, McGee J, Jennings MH, Gonzales-Toledo E, Minagar A: Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-β1b. Mult Scler. 2010, 16: 801-809. 10.1177/1352458510370791.CrossRefPubMed Alexander JS, Harris MK, Wells SR, Mills G, Chalamidas K, Ganta VC, McGee J, Jennings MH, Gonzales-Toledo E, Minagar A: Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-β1b. Mult Scler. 2010, 16: 801-809. 10.1177/1352458510370791.CrossRefPubMed
5.
go back to reference Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007, 8: 345-350.CrossRefPubMed Bettelli E, Oukka M, Kuchroo VK: T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007, 8: 345-350.CrossRefPubMed
6.
go back to reference Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD: Gene expression changes in peripheral blood mononuclear cells from Multiple Sclerosis patients undergoing β-Interferon therapy. J Neurol Sci. 2007, 258: 52-59. 10.1016/j.jns.2007.02.034.CrossRefPubMed Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD: Gene expression changes in peripheral blood mononuclear cells from Multiple Sclerosis patients undergoing β-Interferon therapy. J Neurol Sci. 2007, 258: 52-59. 10.1016/j.jns.2007.02.034.CrossRefPubMed
7.
go back to reference Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F: Increased IL-10 mRNA and IL-23 m RNA expression in multiple sclerosis: interferon-{beta} treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler. 2008, 14: 622-630. 10.1177/1352458507087136.CrossRefPubMed Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F: Increased IL-10 mRNA and IL-23 m RNA expression in multiple sclerosis: interferon-{beta} treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Mult Scler. 2008, 14: 622-630. 10.1177/1352458507087136.CrossRefPubMed
8.
go back to reference Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S: β interferon restricts the inflammatory potential of CD4+ cells through the boost of the TH17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol. 2008, 45: 4008-4019. 10.1016/j.molimm.2008.06.006.CrossRefPubMed Martin-Saavedra FM, Gonzalez-Garcia C, Bravo B, Ballester S: β interferon restricts the inflammatory potential of CD4+ cells through the boost of the TH17 response and the prevalence of naturally occurring T regulatory cells. Mol Immunol. 2008, 45: 4008-4019. 10.1016/j.molimm.2008.06.006.CrossRefPubMed
9.
go back to reference Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C: T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010, 16: 406-412. 10.1038/nm.2110.CrossRefPubMedPubMedCentral Axtell RC, de Jong BA, Boniface K, van der Voort LF, Bhat R, De Sarno P, Naves R, Han M, Zhong F, Castellanos JG, Mair R, Christakos A, Kolkowitz I, Katz L, Killestein J, Polman CH, de Waal Malefyt R, Steinman L, Raman C: T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010, 16: 406-412. 10.1038/nm.2110.CrossRefPubMedPubMedCentral
10.
go back to reference Wandinger KP, Stürzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R: Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol. 2001, 50: 349-357. 10.1002/ana.1096.CrossRefPubMed Wandinger KP, Stürzebecher CS, Bielekova B, Detore G, Rosenwald A, Staudt LM, McFarland HF, Martin R: Complex immunomodulatory effects of interferon-β in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol. 2001, 50: 349-357. 10.1002/ana.1096.CrossRefPubMed
11.
go back to reference Zhang X, Markovic-Plese S: Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg. 2010, 112: 641-645. 10.1016/j.clineuro.2010.04.020.CrossRefPubMed Zhang X, Markovic-Plese S: Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin Neurol Neurosurg. 2010, 112: 641-645. 10.1016/j.clineuro.2010.04.020.CrossRefPubMed
12.
go back to reference van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BMJ, Barkhof F, Oudejans CBM, Polman CH, Killestein J: Spontaneous MxA mRNA level predicts Relapses in patients with recently diagnosed MS. Neurology. 2010, 75: 1228-1233. 10.1212/WNL.0b013e3181f6c556.CrossRefPubMed van der Voort LF, Vennegoor A, Visser A, Knol DL, Uitdehaag BMJ, Barkhof F, Oudejans CBM, Polman CH, Killestein J: Spontaneous MxA mRNA level predicts Relapses in patients with recently diagnosed MS. Neurology. 2010, 75: 1228-1233. 10.1212/WNL.0b013e3181f6c556.CrossRefPubMed
Metadata
Title
Preliminary study: Treatment with intramuscular interferon beta-1a results in increased levels of IL-12Rβ2+ and decreased levels of IL23R+ CD4+ T - Lymphocytes in multiple sclerosis
Authors
Jennifer M Kress-Bennett
Garth D Ehrlich
Ashley Bruno
J Christopher Post
Fen Z Hu
Thomas F Scott
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2011
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/1471-2377-11-155

Other articles of this Issue 1/2011

BMC Neurology 1/2011 Go to the issue